EpiPen litigation comes back to haunt Teva a decade after initial settlements

Between opioid litigation, price fixing claims, generic carve-out feuds—and, now, a class-action lawsuit alleging copycat launch shenanigans—Teva Pharmaceutical has certainly kept the courts busy in recent years.

In the latest legal entanglement, Teva is accused of stalling the rollout of its generic EpiPen in a quid pro quo with the epinephrine injector’s owner, Viatris. In return for the epinephrine launch delay, Viatris promised not to undercut Teva’s branded narcolepsy med Nuvigil with its own generic, according to court documents filed earlier this month.